1 |
An oral controlled release oxymorphone formulation, comprising: a. about 5 mg to about 80 mg of oxymorphone or a pharmaceutically acceptable salt of oxymorphone; and b. a hydrophilic material, wherein upon oral administration of the formulation to a
subject in need of an analgesic effect: (i) the formulation provides detectable blood plasma levels of 6-OH oxymorphone and oxymorphone; (ii) the blood plasma levels of 6-OH oxymorphone and oxymorphone peak within about 1 hour to about 8 hours after administration; (iii) the blood plasma levels of 6-OH oxymorphone and oxymorphone exhibit a ratio of area under the curve (AUC(0 to inf)) of blood plasma level versus time for 6-OH oxymorphone compared to oxymorphone in a range of about 0.5 to about 1.5; (iv) the duration of the analgesic effect is through at least about 12 hours after administration; and (v) the blood plasma levels of oxymorphone exhibit two or three peaks within about 12 hours after administration.
view more
|
Valid (102 and 112)
Entry 96
|
22 |
The tablet of claim 21 wherein about 45% to about 80%, by weight, of the oxymorphone or salt thereof is released from the tablet at about 4 hours in the test, and at least about 80%, by weight, of the oxymorphone or salt thereof is released from the
tablet at about 10 hours in the test.
view more
|
Valid (102 and 112)
Entry 96
|
40 |
The method of claim 38 wherein the difference in the oxymorphone area under the curve AUC<sub>(0-inf) </sub>between fed and fasted conditions is less than 20%.
|
Invalid
Entry 180
|
42 |
The method of claim 38 wherein upon oral administration of the dosage form to the subject under fed or fasting conditions: (i) the dosage form provides detectable blood plasma levels of 6-OH oxymorphone and oxymorphone; (ii) the blood plasma levels
of 6-OH oxymorphone and oxymorphone peak within about 1 hour to about 8 hours after administration; and (iii) the blood plasma levels of 6-OH oxymorphone and oxymorphone exhibit a ratio of AUC(0-inf) of blood plasma level versus time for 6-OH oxymorphone compared to oxymorphone in a range of about 0.5 to about 1.5.
view more
|
Invalid
Entry 180
|
50 |
The composition of claim 49 wherein upon oral administration thereof the oxymorphone AUC<sub>(0-inf) </sub>is no more than 20% higher when the dosage form is administered to the subject under fed as compared to fasted conditions.
|
Valid (102 and 112)
Entry 96
|
54 |
The composition of claim 49 wherein about 45% to about 80%, by weight, of the oxymorphone or salt thereof is released from the tablet at about 4 hours in the test, and at least about 80%, by weight, of the oxymorphone or salt thereof is released from
the tablet at about 10 hours in the test.
view more
|
Valid (102 and 112)
Entry 96
|
57 |
The composition of claim 55, wherein the composition is in the form of a tablet and wherein at least 27%, by weight, of the oxymorphone or salt thereof is released from the tablet at about 1 hour in the test, at least 40%, by weight, of the
oxymorphone or salt thereof is released from the tablet at about 2 hours in the test, at least 50%, by weight, of the oxymorphone or salt thereof is released from the tablet at about 3 hours in the test, at least 64%, by weight, of the oxymorphone or salt thereof is released from the tablet at about 5 hours in the test, at least 70%, by weight, of the oxymorphone or salt thereof is released from the tablet at about 6 hours in the test, at least 79%, by weight, of the oxymorphone or salt thereof is released from the tablet at about 8 hours in the test, at least 85%, by weight, of the oxymorphone or salt thereof is released from the tablet at about 10 hours in the test, and at least 89%, by weight, of the oxymorphone or salt thereof is released from the tablet at about 12 hours in the test.
view more
|
Valid (102 and 112)
Entry 96
|
62 |
The composition of claim 55, wherein the composition is in the form of a tablet and wherein at least 70%, by weight, of the oxymorphone or salt thereof is released from the tablet at about 6 hours in the test.
|
Valid (102 and 112)
Entry 96
|
64 |
The composition of claim 55, wherein the composition is in the form of a tablet and wherein at least 85%, by weight, of the oxymorphone or salt thereof is released from the tablet at about 10 hours in the test.
|
Valid (102 and 112)
Entry 96
|
71 |
The composition of claim 66 wherein the composition is in the form of a tablet and about 45% to about 80%, by weight, of the oxymorphone or salt thereof is released from the tablet at about 4 hours in the test, and at least about 80%, by weight, of
the oxymorphone or salt thereof is released from the tablet at about 10 hours in the test.
view more
|
Valid (102 and 112)
Entry 96
|
73 |
The pharmaceutical composition of claim 72 wherein about 45% to about 80%, by weight, of the oxymorphone or salt thereof is released from the composition after about 4 hours in the test.
|
Valid (102 and 112)
Entry 96
|
74 |
The pharmaceutical composition of claim 72 wherein at least 80%, by weight, of the oxymorphone or salt thereof is released from the composition after about 10 hours in the test.
|
Valid (102 and 112)
Entry 96
|
78 |
The pharmaceutical composition of claim 77 wherein upon oral administration of the dosage form to a human subject in need of an analgesic effect the blood plasma level of oxymorphone displays two or three peaks over about the first 12 hours after
administration; and (i) the dosage form provides detectable blood plasma levels of 6-OH oxymorphone and oxymorphone; (ii) the blood plasma levels of 6-OH oxymorphone and oxymorphone peak within about 1 hour to about 8 hours after administration; (iii) the blood plasma levels of 6-OH oxymorphone and oxymorphone exhibit a ratio of area under the curve (AUC(0 to inf)) of blood plasma level versus time for 6-OH oxymorphone compared to oxymorphone in a range of about 0.5 to about 1.5; and (iv) the duration of the analgesic effect is through at least about 12 hours after administration.
view more
|
Valid (102 and 112)
Entry 96
|
79 |
The pharmaceutical composition of claim 77 wherein about 58% to about 66%, by weight, of the oxymorphone or salt thereof is released from the composition after about 4 hours in the test.
|
Valid (102 and 112)
Entry 96
|
80 |
The pharmaceutical composition of claim 77 wherein about 85% to about 96%, by weight, of the oxymorphone or salt thereof is released from the composition after about 10 hours in the test.
|
Valid (102 and 112)
Entry 96
|
82 |
A method of treating pain in a subject in need thereof, the method comprising administering to the subject the pharmaceutical composition of claim 77 in an amount sufficient to provide the subject with about 5 mg to about 80 mg of oxymorphone or salt
thereof.
view more
|
Valid (102 and 112)
Entry 96
|